Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(98)01885-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can you have a cake and eat it? Comparing reducing mycophenolate versus switching to everolimus for kidney transplants with new-onset BKPyV-DNAemia.
Kidney Int
February 2025
Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel Switzerland. Electronic address:
BK polyomavirus remains a vexing issue in kidney transplantation. There are no antiviral drugs, and solely reducing immunosuppression is recommended for management. However, evidence from randomized controlled studies lacks defining clearance of BK polyomavirus-DNAemia and/or nephropathy as a primary outcome.
View Article and Find Full Text PDFImmunosuppressive therapy and nutritional diseases of patients after kidney transplantation: a systematic review.
BMC Nephrol
January 2025
Department of Clinical Dietetics, Medical University of Warsaw, Erazma Ciolka 27 Street, Warsaw, 01-445, Poland.
Background: Kidney transplantation (kTx) is by far the most effective method of treating end-stage renal disease, with immunosuppressive therapy being obligatory for all, except identical twins. Despite kTx being the most effective treatment for end-stage renal disease, the patients face significant morbidity. They are often burdened with diabetes, anaemia, lipid disorders, all of which pose heightened risks for cardiovascular disease.
View Article and Find Full Text PDFFirst full intracorporeal robotic cystectomy and neobladder in a renal transplant recipient.
J Surg Case Rep
January 2025
UNICAEN, Urology and Transplantation Department, Normandie University, CHU de Caen, Avenue de la Côte de Nacre, Caen 14000, France.
The literature regarding robotic-assisted radical cystectomy in kidney transplant recipients is limited. We present the first reported case of robotic-assisted radical cystectomy with a full intracorporeal orthotopic neobladder in a kidney transplant recipient. A 36-year-old man was diagnosed with muscle-invasive urothelial carcinoma 12 years after kidney transplantation.
View Article and Find Full Text PDFAssociation between Everolimus Combination Therapy and Cancer Risk after Liver Transplantation: A Nationwide Population-based Quasi-Cohort Study.
Am J Transplant
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea. Electronic address:
The potential of everolimus in reducing hepatocellular carcinoma (HCC) among recipients following liver transplantation has been reported. This nationwide population-based quasi-cohort study investigated whether combining everolimus with calcineurin inhibitor therapy affects the risk of HCC and extrahepatic cancers compared to a time-duration-matched cohort of recipients not receiving everolimus. Using data covering the entire population from Korea, liver transplant recipients who had initiated immunosuppressants between June 2015 and February 2020 were collected and divided into two groups: the everolimus combination and non-combination groups.
View Article and Find Full Text PDFDevelopment and Clinical Validation of Model-Informed Precision Dosing for Everolimus in Liver Transplant Recipients.
ACS Pharmacol Transl Sci
January 2025
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Everolimus presents significant dosing challenges due to between- and within-patient pharmacokinetic variabilities. This study aimed to develop and validate a model-informed precision dosing strategy for everolimus in liver transplant recipients. The dosing strategy was initially developed using retrospective data, employing nonlinear mixed-effects modeling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!